Navigation Links
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
Date:12/6/2012

uing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended September 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

CONTACTS:
Investors: Bernie Hertel,
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
5. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
(Date:7/10/2014)... WASHINGTON D.C., June 17, 2014 Using microscopic ... of specific gases, researchers at MIT,s Quantum Photonics ... detection levels in the parts-per-billion range. Optical sensors ... to their high signal-to-noise ratio, compact, lightweight nature, ... optical gas sensors had been developed before, the ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... batteries that power our laptops and electric vehicles could ... charge with the help of a sponge-like silicon material. ... the graphite traditionally used in one of the battery,s ... energy storage capacity of graphite. A paper describing the ... today in Nature Communications . , "Silicon has ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... Inc. (Nasdaq:,NVAX) Novavax today announced Chief Executive Officer Dr. ... Conference at,5:05 am Eastern time (11:05 am CEST) on ... the company announced today., Dr. Singhvi will provide ... and its unique manufacturing solution. A,link to an audio ...
... Pharmaceuticals,Corp. (Nasdaq: MEMY ) today reported its ... 2008., "We had a productive start to ... our operations to advance four high-value,programs," said Vaughn ... decision to license R3487/MEM 3454 highlights the potential,of ...
... CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech ... it has,received a letter of approval from ... (MHRA) for its Clinical Trial Application (CTA),to ... intravenous administration of,REOLYSIN(R) in combination with paclitaxel ...
Cached Biology Technology:Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 7Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... good grade, or promotion wonderfully concentrates the mind, ... responsible for such reward-motivated learning. , In an ... Adcock and colleagues report brain-scanning studies in humans ... the brain's learning and memory regions to promote ...
... by the University of California, Berkeley, and Lawrence Berkeley National ... cells that can be flipped on and off as easily ... like these could trigger a chemical reaction, initiate a muscle ... all at the flash of a light. , One ...
... molecular denominator in aging and many age-related diseases is oxidative ... HMS associate professor of pathology. The skin of a bitten ... in some ways that is a good metaphor for the ... types of cells over time. , Humans and other organisms ...
Cached Biology News:The brain's motivation station 2Light-sensitive photoswitches could restore sight to those with macular degeneration 2Light-sensitive photoswitches could restore sight to those with macular degeneration 3Free radical cell death switch identified 2
... SizeSep 400 Spun Columns, 10. *SizeSep 400 ... > 400 base pairs in length. ... CL-4B and pre-equilibrated in distilled water containing 0.15% ... than ~ 400 base pairs. *Extremely ...
... 25 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
... are complete ready-to-use reagents for the isolation ... specifically formulated for the isolation of genomic ... specifically formulated for the isolation of genomic ... DNAzol Reagents can be used for restriction ...
Apoptosis Detection Systems and Reagents...
Biology Products: